BioNews Services followed up its comprehensive onsite news coverage of the 4th Systemic Sclerosis World Congress last month with yet another patient-focused feature of a critically important health conference. In late March, BioNews’ Multiple Sclerosis News Today was on-site at #CONy16 — the 10th World Congress on Controversies in Neurology, to primarily cover MS news as well as presentations on Parkinson’s Disease.
CONy is a unique health conference in that instead of having researchers offer presentations and lectures, controversial and open topics pertaining to disease research and management are debated by two scientists who hold opposing views. This interview with Dr. Amos Korczyn, CONy16 Co-Chairperson, conduced by BioNews services Social Media Director Isaura Santos, highlights the uniqueness of the conference:
BioNews chose to cover the conference because of the topics covered in the debates, knowing that many multiple sclerosis and Parkinson’s patients have strong opinions on these topics themselves. Multiple Sclerosis News Today‘s on-site team coverage included chief correspondent Dr. Ana de Barros, Social Media Director Isaura Santos, and Social Media Manager Marta Ribeiro, while Managing Editor Patricia Silva and Social Media Manager Andreia Peixoto along with a team of science writers published exclusive news, social media, and video content in real time.
Valuable MS Stories That the Health Media Missed
Multiple Sclerosis News Today was the only health and biotech website to cover CONy. As a result, its exclusive coverage of the debates offered the multiple sclerosis community insights into important topics and discussions that the rest of the media missed. Here are the featured articles from the conference that allowed patients to read about what is currently hot in MS research, treatment, and disease management:
- CONy16: MS Researchers Question Possible Long-term Benefits of Remyelination TherapiesMultiple sclerosis was a main focus at the four-day 10th World Congress on Controversies in Neurology (CONy), in Lisbon, Portugal, that concluded on March 20. Among the topics of debate was demyelination as the disease’s main pathogenic precursor and the clinical potential of remyelination. The debate, titled “Can we expect long-term clinical improvement thr […]
- CONy16: Pros and Cons of MS Drugs Targeting Immune Cells Other Than B-cells DebatedClinical trials have shown that ocrelizumab — an antibody targeting B-cells — is effective in multiple sclerosis (MS). As a result, some researchers and clinicians claim that B-cell depletion is a sufficient therapy in MS, and that drugs targeting other immune cells are obsolete. Not everyone agrees. A debate at the 10th World Congress on Controversies […] T […]
- CONy16: Should RRMS Disease-Modifying Drugs Be Used to Treat Secondary Progressive MS?A major dilemma facing clinicians is whether to continue treatment with disease-modifying drugs, effective in relapsing-remitting multiple sclerosis (RRMS), as the disease progresses to secondary progressive MS (SPMS). In SPMS, these treatments seem to lose their benefits and — as they are often associated with severe side effects and high costs — clinician […]
- CONy16: Sanofi Genzyme Symposium on MS Therapies Targeting T and B Cells; Exclusive Interview with Lead ResearcherSanofi Genzyme, one of the companies participating in the four-day 10th World Congress on Controversies in Neurology (CONy) in Lisbon, Portugal, that concluded on March 20, 2016, supported several symposiums focused on multiple sclerosis (MS) — including one on B-cell and T-cell therapies. For over a decade, Sanofi Genzyme has worked to develop effective the […]
- CONy16: Debate Weighs MS Therapy Risks of Infections Like PML in Terms of Benefits OfferedCertain therapies used to treat multiple sclerosis (MS) have been associated with opportunistic infections of the central nervous system, including progressive multifocal leukoencephalopathy (PML), a rare but often fatal brain disorder caused by the John Cunningham (JC) virus. The question of whether the risk for opportunistic infections to MS patients outwe […]
- #CONy16 – Exclusive Interview with Dr Michael Geschwindhttp://multiplesclerosisnewstoday.com/wp-content/uploads/videos/Dr-Michael-Geschwind.mp4 Multiple Sclerosis News Today correspondent conducts an exclusive interview with Dr Michael Geschwind, Professor at UCSF School of Medicine. Follow our live coverage of #CONy16 on Twitter and here: http://bit.ly/1LqVV32 The post #CONy16 – Exclusive Interview with Dr Mich […]
- #CONy16 – Exclusive Interview with Professor Xavier Montalbanhttp://multiplesclerosisnewstoday.com/wp-content/uploads/videos/Professor-Xavier-Montalban.mp4 Multiple Sclerosis News Today correspondent conducts an exclusive interview with Professor Xavier Montalban from the Vall d’Hebron University Hospital, Barcelona, Spain, and Director of the Multiple Sclerosis Centre of Catalonia, Spain Follow our live coverage of # […]
- #CONy16 – Exclusive Interview with Dr. Florian Deisenhammerhttp://multiplesclerosisnewstoday.com/wp-content/uploads/videos/Dr-Florian-Deisenhammer.mp4 Multiple Sclerosis News Today correspondent conducts an exclusive interview with Dr. Florian Deisenhammer, Professor of Neurology, Clinical Department of Neurology, Neuroimmunology Laboratory, Innsbruck Medical University, Innsbruck, Austria. Follow our live coverage […]
Remyelination, targeting B-cells, Vitamin D, using RRMS drugs to manage progressive MS — these are all topics that directly interest and pertain to the MS patient population, and BioNews Services provided unique insights into the debates surrounding these topics, including live-blogging the debates on Twitter as well as this series of exclusive video interviews:
Interview with Professor Xavier Montalban, Vall d’Hebron University Hospital, Barcelona, and MS MRI expert:
Interview with Dr. Florian Deisenhammer, Innsbruck Medical University, Austria
Interview with Professor Vitor Oliveira, CONy16 Co-Chairperson
Interview with Dr. Michael Geschwind, Professor of Neurology at UCSF School of Medicine
CONy16 Coverage By the Numbers
BioNews uses Twitter to live-tweet conferences and events, and in the case of CONy16, the platform served as a barometer for how engaged the MS and Parkinson’s communities were in terms of live news coverage. By the end of the conference, Multiple Sclerosis News Today was the clear leader in terms of influence on Twitter:
— Symplur Hashtags (@healthhashtags) March 20, 2016
Coverage of the event via our social media and articles led to an incredible influx of readers to the site. Using Chartbeat real-time analytics, Multiple Sclerosis News Today boasted amazing on-site numbers during the event:
The end result was a tremendous amount of high-quality web traffic to Multiple Sclerosis News Today. Google Analytics indicates that CONy content dominated MS traffic:
Facebook also played an important role in broadcasting news content from CONy16. Facebook analytics reveal that the days of the conference broke through page benchmarks in terms of post reach:
. . . , as well as reactions, comments, and shares:
Comprehensive On-site News Coverage Inspired By the Networks
No other health news media agency offers the same level of comprehensive, wall-to-wall on-site coverage as BioNews Services’ Event Coverage. Our approach is akin to that of television news networks that cover major events with a team of on-site correspondents and supporting multimedia professionals, albeit with a leaner, more agile team and workflow. The combination of science writers, social media experts, and audio-visual professionals allow us to offer event coverage that brings the experience of the conference directly to patients. This is particularly advantageous for health and biotech conference and event planners, since often times, the events are dominated by researchers, physicians, and industry professionals. Because patients are often unable to attend the conferences, BioNews’ coverage gives conference planners as well as industry sponsors a chance to reach out to the patient community at these events and let them know what they are working on in terms of improving treatment and care. Our correspondents, most of whom are PhD researchers, are particularly adept at taking technical information presented at the conference and translating them into articles that patients can understand.
— MS News Today (@MSNewsToday) March 19, 2016
— MS News Today (@MSNewsToday) March 19, 2016
At BioNews Services, our content model is completely different: we build niche, disease-specific websites and social media assets to build patient communities online. As more and more patients seek to take control of their own disease management and learn everything they can about the diseases and conditions that they suffer from, the media can no longer simply focus on educating physicians and engaging researchers. The new approach is a “bottom-up” one, where patients, armed with the latest knowledge, can be better engaged in treatment decisions with their healthcare team.
For conferences as well as corporate sponsors looking for increased visibility for their brand, product, or research, BioNews offers conference news services that can deliver the rich, valuable conference experience to not only researchers and physicians who could not attend, but patients as well. The goodwill and engagement created from this coverage is integral to increasing clinical trial participation and patient awareness — two areas of research and treatment that are sorely lacking.
Click here to learn more about BioNews’ conference news services.
- Cure SMA Launches National Newborn Screening Campaign July 13, 2017
- Innovate Seeks Orphan Drug Status for Pediatric Ulcerative Colitis Therapy Candidate INN-108 July 13, 2017
- Northwestern Researchers Find Immune Cells Link to Fibrosis, Reversing Previous Theories July 13, 2017
- People with Chorea Can Switch from Xenazine To Austedo Safely, Phase 3 Clinical Trial Shows July 13, 2017
- Imaging Techniques Combo Helps Better Evaluate Bone Disease Risk in Gaucher Patients, Study Finds July 13, 2017
- Charlie Gard Case Captures Vast and Unmet Needs of People wth Mitochondrial Disease, Groups Say July 13, 2017
- FDA Committee Recommends Approval of Mylotarg to Treat Newly Diagnosed AML July 13, 2017
- Trial of Miltuximab in Prostate, Other Cancers Gets Nod to Enroll Additional Patients July 13, 2017
- Northwestern Researchers Find New Link Between Immune Cells and Pulmonary Fibrosis July 13, 2017
- Spine Inflammation Might Explain Why Motor Neurons Die in ALS, Researchers Suggest July 13, 2017